Eris Lifesciences Limited

NSE: ERIS · Healthcare

₹1,234.10+0.34%06 Nov 2026

Ask the data

Instant answers about Eris Lifesciences Limited — computed from its filings, no language model

Market cap₹17,117 cr

Current price₹1,234.10

High / Low₹1,701 / ₹1,096

P/E24.2

P/B4.13

Book value₹298.8

ROE17.1%

ROCE12.7%

Debt / equity0.57

Dividend yield—

EPS (TTM)₹51.02

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	856	982	1,074	1,212	1,347	1,685	2,009	2,894	3,129
EBITDA	322	345	368	431	485	537	675	1,017	1,120
Operating margin	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%	35.2%	35.8%
Interest	11	23	2	2	4	26	85	231	193
Depreciation	26	36	50	43	65	117	183	315	280
Profit before tax	312	317	331	394	442	405	431	489	638
Tax	17	26	35	39	36	30	34	114	-9
Net profit	294	291	297	355	406	382	392	352	620
EPS ₹	21.39	21.15	21.61	26.16	29.89	28.10	28.82	25.85	45.33
Operating cash flow	—	—	—	—	378	292	486	1,065	538
Capex	—	—	—	—	121	841	129	155	297
Dividend paid	—	—	—	—	82	100	0	100	0
Total assets	—	—	—	—	—	3,667	7,049	7,033	7,366
Equity	—	—	—	—	—	2,196	2,586	2,854	3,903

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	212	251	264	252	215	274	285	266	249	293	330	310	278	349	360	332	306	461	423	403	467	505	486	551	720	739	727	705	773	792	807	757	873	892
Operating profit	72	89	101	94	62	105	110	77	77	104	125	107	95	127	140	122	97	151	137	119	170	181	176	148	250	262	250	252	277	288	282	274	296	309
Operating margin	33.8%	35.3%	38.1%	37.1%	28.9%	38.1%	38.6%	28.8%	31.1%	35.5%	37.8%	34.5%	34.0%	36.2%	38.9%	36.6%	31.7%	32.9%	32.4%	29.5%	36.4%	35.8%	36.1%	26.9%	34.7%	35.5%	34.4%	35.8%	35.8%	36.4%	34.9%	36.2%	33.9%	34.7%
Other income	7	4	6	10	12	3	5	8	-1	1	2	3	2	6	7	5	8	5	2	1	1	3	4	15	2	7	4	8	3	3	0	2	2	3
Interest	8	7	6	5	4	1	1	0	0	0	0	0	1	1	1	1	1	7	3	9	17	16	18	33	60	59	57	54	49	50	49	46	47	46
Depreciation	9	7	8	10	11	12	12	13	14	10	11	11	11	15	15	17	18	29	30	35	41	42	46	54	76	80	81	77	71	69	70	70	72	73
Profit before tax	62	78	92	89	58	95	103	72	62	95	116	99	85	117	131	109	85	121	107	76	112	126	116	77	115	129	116	129	160	172	145	161	180	157
Tax	6	6	7	9	4	11	10	9	5	6	8	9	16	10	12	8	5	2	6	14	19	4	14	-3	26	33	29	27	36	38	37	-120	36	-31
Net profit	56	71	85	80	54	84	93	63	56	89	108	90	68	107	118	101	80	120	102	65	95	123	103	71	83	92	84	94	118	120	100	282	142	184
EPS ₹	4.06	5.18	6.20	5.83	3.93	6.11	6.74	4.62	4.13	6.56	7.93	6.64	5.03	7.86	8.71	7.41	5.91	8.84	7.49	4.81	6.97	9.08	7.55	5.22	6.11	6.73	6.15	6.90	8.66	8.82	7.32	20.60	10.28	13.26
Revenue YoY	—	—	—	—	1.2%	9.4%	7.8%	5.5%	15.7%	6.9%	15.9%	16.5%	11.9%	19.1%	9.0%	7.0%	10.0%	28.0%	27.4%	31.7%	—	9.7%	14.9%	36.8%	54.2%	46.2%	49.6%	28.0%	7.4%	7.2%	11.0%	7.3%	13.0%	12.6%
Profit YoY	—	—	—	—	-3.0%	18.0%	8.7%	-20.8%	4.0%	5.9%	16.2%	42.0%	21.3%	19.8%	9.9%	11.8%	17.7%	1.6%	1.1%	-18.5%	—	2.6%	0.9%	8.5%	-12.3%	-25.8%	-18.6%	32.2%	41.8%	31.2%	19.3%	200.1%	20.7%	52.9%

Earlier results (standalone, Jun '17 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Eris Lifesciences Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Quarters

	JUN '17†	SEP '17†	DEC '17†
Revenue	162	222	182
Operating profit	69	95	79
Operating margin	42.6%	43.0%	43.5%
Other income	7	7	6
Interest	—	—	3
Depreciation	4	4	6
Profit before tax	72	98	77
Tax	2	6	3
Net profit	70	92	74
EPS ₹	5.09	6.71	5.38

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 28 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	17.4%	16.0%	16.0%	15.2%	14.7%	12.6%	11.9%	12.3%	13.6%	13.4%	14.0%	15.9%	16.5%	17.1%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	—	—	14.9%	14.6%	15.4%	9.7%	10.6%	11.0%	11.8%	13.5%	14.1%	14.4%	14.7%	13.4%	13.7%	12.7%
Net margin	29.9%	29.6%	30.2%	30.3%	28.3%	27.6%	27.6%	27.8%	29.0%	29.3%	29.4%	29.6%	29.9%	30.1%	21.8%	21.4%	20.8%	19.5%	16.8%	14.0%	12.0%	12.2%	13.1%	13.9%	14.0%	19.8%	19.9%	21.3%
EBITDA margin	36.2%	35.1%	35.9%	36.1%	34.0%	34.3%	33.7%	33.6%	35.0%	35.5%	35.7%	36.1%	36.6%	36.0%	32.9%	33.8%	34.7%	33.6%	33.4%	33.5%	33.3%	35.1%	35.4%	35.6%	35.7%	35.8%	35.3%	34.9%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.38	0.33	0.33	1.06	1.06	0.99	0.99	0.87	0.87	0.77	0.77	0.59	0.59	0.57
Interest coverage	13.25	14.86	21.03	32.48	53.58	154.40	200.44	216.09	231.61	220.17	193.15	155.81	129.74	107.55	12.46	10.25	8.10	6.08	4.40	3.56	3.08	3.12	3.43	3.75	4.01	4.31	4.45	4.43
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.48	0.46	0.48	0.29	0.32	0.36	0.39	0.41	0.42	0.42	0.43	0.42	0.44	0.44

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	14	14	14	14	14	14	14	14	14
Other equity / reserves	2,013	2,182	2,398	2,573	2,758	2,841	3,078	3,889	4,130
Total equity	2,027	2,196	2,412	2,586	2,771	2,854	3,091	3,903	4,144
Borrowings	216	830	786	2,735	2,735	2,478	2,389	2,310	2,382
Current liabilities	360	443	497	2,532	1,234	1,381	1,523	2,077	2,681
Non-current liabilities	452	1,003	950	1,295	2,610	2,380	2,134	1,393	758
Total assets	2,869	3,667	3,875	7,049	7,022	7,033	7,160	7,366	7,581
Property, plant & equipment	191	356	365	505	513	662	676	708	716
Capital work-in-progress	108	21	58	19	7	67	122	171	395
Investments	4	37	22	16	79	67	68	62	60
Inventories	109	131	139	189	256	335	409	437	474
Receivables	296	293	350	422	488	459	645	680	632
Cash & equivalents	68	56	173	94	150	200	56	55	238

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	378	292	486	1,065	538
Cash from investing	-320	-975	-1,828	-80	-369
Cash from financing	-45	688	1,380	-881	-314
Capex	121	841	129	155	297
Free cash flow	257	-550	357	910	241
Dividends paid	82	100	0	100	0

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹716 cr9%

CWIP

₹395 cr5%

Investments

₹60 cr1%

Inventories

₹474 cr6%

Receivables

₹632 cr8%

Cash & equivalents

₹238 cr3%

Other assets

₹5,066 cr67%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Eris Lifesciences Limited	17,117	1,234.10	24.2	4.13	17.1%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+7.7%

6 months-10.8%

1 year-24.3%

3Y CAGR+12.7%

5Y CAGR+8.7%

10Y CAGR—

50-day avg₹1,229.63

200-day avg₹1,344.08

RSI (14)65

FAQs

What is the share price of Eris Lifesciences Limited?

Eris Lifesciences Limited (ERIS) closed at ₹1,234.10 on NSE on 06 Nov 2026.

What is the market cap of Eris Lifesciences Limited?

₹17,117 crore at the latest close.

What is the P/E ratio of Eris Lifesciences Limited?

24.2, on trailing-twelve-month earnings from its filings.

How fast is Eris Lifesciences Limited growing?

Eris Lifesciences Limited: revenue has compounded at 22.9% a year over three years; net profit at 17.5% a year. Latest-quarter revenue is up 12.6% year on year, profit up 52.9%.

How profitable is Eris Lifesciences Limited?

On a trailing-twelve-month basis return on equity is 17.1%, return on capital employed 12.7%, operating margin 34.9%, net margin 21.3%.

How much debt does Eris Lifesciences Limited have?

Eris Lifesciences Limited is moderately geared: debt to equity is 0.57 with borrowings of ₹2,382 cr against cash of ₹238 cr (balance sheet of 2026-09-30). Operating profit covers interest 4.4 times.

Financials parsed from Eris Lifesciences Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.